Kathryn Kousda

Executive Officer, Director at Vaxess Technologies.

Raised on Vaxess Technologies filings

$73.6M

of $103.5M offered across 3 Form D filings

Form D filings: 3
Teammates: 12
Last filing: Mar 19, 2026

Company

Vaxess Technologies

Biotech · Cambridge, MA

Dissolvable microarray patches for vaccines

Dissolvable microarray patches for vaccines

Investors: 3
Still open: $29.9M

Investors: 3
Sector: Biotech
HQ: Cambridge, MA

Vaxess Technologies filings

Vaxess Technologies Form D filings
Filed	Security	Sold of offered	Filing
Mar 19, 2026	Equity	$57.3M/ $83.5M	Form D
Sep 10, 2025	Debt	$7.9M/ $10M	Form D
Feb 26, 2025	Debt	$8.4M/ $10M	Form D

EquityFiled Mar 19, 2026Form D
$57.3M/ $83.5M
DebtFiled Sep 10, 2025Form D
$7.9M/ $10M
DebtFiled Feb 26, 2025Form D
$8.4M/ $10M

Works with

Also named on Vaxess Technologies filings

Rachel ShaPresident, Form D signerForm D signer Weiner TilsnerExecutive Officer Linda TusseyExecutive Officer John SpiridigliozziExecutive Officer Jonathan KlugeExecutive Officer Kathryn KosudaExecutive Officer, Director Lynda TusseyExecutive Officer Matthew DirckxExecutive Officer Ann DeWittDirector Fenel EloiDirector Livio ValentiExecutive Officer Peter KolchinskyDirector